New imaging test for HER2-positive cancers
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with stomach, breast, or bladder cancer that is HER2-positive (a certain protein on the cancer cells).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, and kidney function are within acceptable levels.
- You are not pregnant and agree to use birth control during the study.
- You do not have certain serious medical conditions like uncontrolled diabetes, recent heart attack, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a radioactive tracer to take pictures of tumors that have a protein called HER2. It may help doctors see where the cancer is in your body and could guide future treatment decisions.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.